The Hatter Cardiovascular Institute as part of both the Institute of Cardiovascular Sciences and the Research Department of Cardiovascular Medicine at University College London, is an established scientific research facility which seeks to be at the forefront of bench to bedside science and therapeutic development.
In this respect, the major component of research focuses on investigating new treatment strategies for protecting the heart from acute ischaemia-reperfusion injury - so called cardioprotection.
This is specifically related to the concept of "myocardial and remote preconditioning and postconditioning", potent endogenous adaptive mechanisms for protecting the heart against ischaemia-reperfusion injury.
Full translational spectrum
The research undertaken at the Hatter Cardiovascular Institute covers the full translational spectrum from isolated cell based studies through to whole organ systems and ultimately to the patient in the clinical setting.
Working with models
The Hatter Institute comprises both basic and clinical scientists working in unison, using a range of experimental models and methods including specific molecular biological, biochemical and pharmacological techniques as well as clinically-directed research.
In addition to work investigating whole-heart cardioprotection, we are working with cellular models. This leads to developing new therapeutic strategies to protect the myocardium from reperfusion-induced injury. This work is based upon our understanding of pro-survival signal transduction pathways and the contribution of mitochondria to cell survival that can be exploited to the benefit of the patient with ischaemic heart disease.
BHF Grant Awarded to Dr Sean Davidson
BHF Grant Awarded to Dr Sean Davidson in November 2016 for research into a 3 year project entitled "The Role of the Individual P13K isoforms in Cardioprotection